PerkinElmer establishes wholly owned subsidiary in India
PerkinElmer has announced that it has acquired the remaining minority interest in PerkinElmer India from Labindia Instruments. The transaction establishes PerkinElmer India as a wholly owned subsidiary of PerkinElmer and underscores the company's commitment to supporting customers in India's thriving life science and analytical instrumentation markets.
"India represents a key growth market for PerkinElmer and we are committed to supporting the changing needs of the country's rapidly expanding health sciences market," said Gregory L Summe, chairman and chief executive officer, PerkinElmer. "The establishment of a 100 percent direct operation in India will allow our customers to maintain their strong relationships with in-country sales and service experts, while providing them an increased level of applications and technical support, as well as direct access to a wider range of PerkinElmer products."
Waters wins Omega Award
For the sixth consecutive year, Waters Corporation has been named the recipient of the 2006 Omega NorthFace ScoreBoard Award. This award recognizes Waters ongoing commitment to deliver best-in-class services for high performance liquid chromatography (HPLC), UltraPerformance LC (UPLC) and mass spectrometry (MS) systems. As an independent quality auditing firm, Omega created the NorthFace ScoreBoard Award program in 2000 to recognize organizations who not only offer exemplary service to their customers, but who also center their existence on a deep commitment to exceeding customer expectations.
Neogenix, Goodwin sign pact
Neogenix Oncology (Neogenix) and Goodwin Biotechnology (GBI) have announced that they have entered into an agreement for process development and manufacturing of Neogenix's first therapeutic product, NPC-1C, a novel monoclonal antibody intended for the treatment of advanced pancreatic cancer. On successful completion of this phase of development, and with FDA approval, Neogenix will begin Phase I and Phase II trials of the product, which are currently planned for the first half of 2008.
"Entering this next phase of development with NPC-1C represents an important milestone for our company," said Myron Arlen, Neogenix CEO and founder. "We look forward to working closely with GBI to produce a high quality antibody that will allow us to enter Phase I and II trials as soon as possible."
"We strive to partner fully with our clients," commented Stephanie Finnegan, CEO of GBI. "Our founding mission, fifteen years ago, was to assist companies in moving products from the research bench into and through human clinical trials. While it is always gratifying to help in this way, it is especially rewarding to assist companies such as Neogenix with treatments for non-recourse diseases such as pancreatic cancer, an especially insidious killer."
Pall opens R&D and tech support center in India
Kenneth Harris, president, BioSciences at Pall Corp, inaugurating Pall's life sciences Center of Excellence (CoE) in Bangalore. Dr MRS Rao, president, Jawaharlal Nehru Center for Advanced Scientific Research, Bangalore (second from left) and Vinay Gupta, managing director, Pall India (extreme right) look on.
Pall opened its life sciences center in Bangalore to provide 24X7 technical support to its Asian and global customers. The $5-6 million, 20,000-sft, state-of-the-art proteomics laboratory is the first of its kind in India. It is part of Pall Corporation's life sciences Center of Excellence (CoE).
Apart from the proteomics laboratory, the CoE houses a validation laboratory and a training facility. A first-of-its-kind the CoE is part of Pall Corporation's global initiative to align with customers worldwide. This CoE will work in tandem with Pall Corp's other such CoEs, in Europe and Western Hemisphere, to deliver 24x7 support to its customers. It has begun operations with 30 scientists on its rolls. "This likely to go up to 60," informed Vinay Gupta, managing director, Pall India.
The Bangalore center will also do a lot of research and development in tandem with Pall's research centers across the US and Europe.
Pall life sciences division currently constitutes 40 percent of Pall Corporation, which today is a $2 billion enterprise focused on fluid management. The company's sales for life sciences in 2006 stood at $796.3 million.
According to Kenneth Harris, president, BioSciences at Pall Corp, India's reputation in life sciences spanning biopharma, research, development and production made it the company's strategic choice for setting up Pall's Asia CoE in Bangalore. "The market opportunity that the country offers and the large pool of qualified scientists is what went in favor of India and Bangalore," he said. Terming it as the world's fastest growing biotech market Harris elaborated on the business case for India.
"With the Pall CoE going functional, the natural convergence of technical expertise and infrastructure will lead to faster drug development," summarized Dr MRS Rao, president of the Jawaharlal Nehru Center for Advanced Scientific Research, Bangalore. He was the chief guest at the inauguration function. He lauded the company's initiative of setting up the country's first proteomics laboratory. "Proteomics and Genomics are the two arms of the modern biotechnology research," said Dr Rao, making a point. He is a leader for India's national research program on cancer genomics.
Sartorius AG combines its biotech division with Stedim Biosystems
Sartorius AG has signed a binding agreement with the biopharmaceutical
supplier Stedim Biosystems SA, a company listed on the Paris stock exchange, and
its major shareholders. Under the terms of this agreement, Sartorius acquires a
substantial stake in Stedim and combines its biotechnology division with Stedim's
business. Sartorius will pay 43 Euros per share. Upon completion of this
transaction, Sartorius will become Stedim's majority owner controlling the
Through the combination of the Sartorius and Stedim biotech businesses, Sartorius is substantially strengthening its position as a technology provider to the fast growing biopharmaceutical market. Stedim's board supports this deal. The overall transaction, which is subject to approval by Stedim's shareholders and to regulatory clearance, is expected to be completed in summer 2007. The combined company will be named Sartorius Stedim Biotech SA.
Dr Joachim Kreuzburg, CEO and chairman of the executive board of Sartorius, said, "This transaction significantly accelerates our strategy to offer customers fully integrated solutions for next generation biopharmaceutical manufacturing. It brings together two passionately innovative technology leaders who both have a strong customer base and who share a common vision. Given the strong double-digit growth rates in the biopharmaceutical markets and the shift in our markets toward disposable solutions, this is the ideal time for our biotech division and Stedim to come together."
BioTek Instruments develops automation technology to aid in blood banking tests
BioTek Instruments has developed in partnership with Immucor (Norcross, GA), an automated benchtop assay instrument for use in the blood transfusion industry. Manufactured by BioTek exclusively for Immucor, the GalileoÂ Echo provides small- to medium-sized hospital blood bank laboratories with walk-away automation of tests such as ABO grouping and Rh (D) typing, detection/identification of IgG red blood cell antibodies, compatibility testing and red blood cell phenotyping for significant increases in productivity and patient safety while taking less time than other methods.
The Galileo Echo instrument was recently cleared by the FDA for marketing in the US, and also received a CE mark, along with its associated reagents, for distribution in Europe.